Search

Your search keyword '"Dignass, A."' showing total 2,171 results

Search Constraints

Start Over You searched for: Author "Dignass, A." Remove constraint Author: "Dignass, A."
2,171 results on '"Dignass, A."'

Search Results

2. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice

3. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis.

15. Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials

16. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

19. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries

20. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

21. AB1410 EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

22. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

23. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

24. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

25. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

29. Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice : International Delphi Consensus Recommendations

30. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn" der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline.

31. Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.

33. Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis

34. Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials

35. COMPARATIVE EFFICACY AND SAFETY OF SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE AND ULCERATIVE COLITIS: AN INDIRECT COMPARISON FROM RANDOMIZED CONTROLLED TRIALS

36. DOP52 Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12

38. DOP49 Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study

42. P954 Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study

44. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

46. International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients

48. Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study

49. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis

50. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).

Catalog

Books, media, physical & digital resources